reSee.it Podcast Summary
Jesse Michels sits down with Martin Shkreli for a long, no-holds-barred talk about gain-of-function debates, reality, and intelligence. Shkreli argues the mind is a classical computer, though a fairly insignificant one, and he weighs whether we’ve passed the Turing test. He frames his public persona as a lens on a larger system, recalling the Daraprim episode—the price jumped from 13.50 to over 700—as a case study in how pricing reflects broader healthcare and regulatory structures, not just production costs. He notes that profiteering in medicine was legal, which he calls the true scandal, and he shares a fascination with Alan Turing, Enigma, and early computing, including owning an Enigma machine.
Turning to AI and reality, the conversation probes whether the mind is a computer and whether we’ve already passed the Turing test. Shkreli says yes, the mind is a classical computer, and he describes AI progress as a humbling, accelerating trend that one cannot stop. He entertains simulation and mind-over-matter ideas, referencing Turing’s poems and musings, parapsychology, and the random-event generator concept. He envisions a future where AI–perhaps with instantiated bodies–gains rights and interacts with humans, while noting that technologies like GPT-3 and Dolly are making progress that reduces human centrality and challenges human self‑image.
Revisiting the drug industry, Shkreli details the Daraprim episode as emblematic of a system that enables dramatic price shifts. He argues doctors don’t always choose the cheapest option because of habit, information gaps, or market dynamics, citing Bactrim as a cheaper alternative and AbbVie’s Norvir as another price example. He points to the DESI-era grandfathering of old medicines and contends that the broader problem isn’t just the price of one drug but the incentives that reward more treatments over cures. He acknowledges some value in pharma outreach and education, while insisting the overall system misaligns access, innovation, and affordability.
Beyond medicine, the interview traces a software startup vision: distributed chemistry computation using AlphaFold-enabled docking and crypto incentives to lower barriers to high-throughput screening. He cites SETI@home and Folding@home as precedents and contrasts distributed ideas with DeepMind’s centralized breakthroughs. The dialogue drifts to Satoshi, blockchain, and the promise of real-world utility from encryption and crypto in science. Personal life topics appear—dating spreadsheets, polyamory, and reflections on love and family—while the thread remains that future science will demand balancing audacious ambitions with practical ethics and human needs. He also discusses his media persona and the public's reaction to his actions.